These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23117769)

  • 1. Inclusion of comparative effectiveness data in high-risk cardiovascular device studies at the time of premarket approval.
    Chen CE; Dhruva SS; Redberg RF
    JAMA; 2012 Nov; 308(17):1740-2. PubMed ID: 23117769
    [No Abstract]   [Full Text] [Related]  

  • 2. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study.
    Phillips AT; Rathi VK; Ross JS
    JAMA Intern Med; 2016 Apr; 176(4):551-2. PubMed ID: 26902933
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence strength in FDA premarket approval of cardiovascular devices.
    Kong DF; Hasselblad V; Krucoff MW
    JAMA; 2010 Apr; 303(16):1599-600; author reply 1600-1. PubMed ID: 20424248
    [No Abstract]   [Full Text] [Related]  

  • 4. Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007.
    Kramer DB; Mallis E; Zuckerman BD; Zimmerman BA; Maisel WH
    Am J Ther; 2010; 17(1):2-7. PubMed ID: 20038828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular device development: an FDA perspective.
    Zuckerman BD; Muni NI
    Am J Ther; 2005; 12(2):176-8. PubMed ID: 15767836
    [No Abstract]   [Full Text] [Related]  

  • 6. Building comparative efficacy and tolerability into the FDA approval process.
    O'Connor AB
    JAMA; 2010 Mar; 303(10):979-80. PubMed ID: 20215612
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmaceuticals and medical devices: medical devices. Year end issue brief.
    Tiffany S
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-19. PubMed ID: 18345548
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessment of Clinical Trial Evidence for High-Risk Cardiovascular Devices Approved Under the Food and Drug Administration Priority Review Program.
    Jones LC; Dhruva SS; Redberg RF
    JAMA Intern Med; 2018 Oct; 178(10):1418-1420. PubMed ID: 30178044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The FDA's role in medical device clinical studies of human subjects.
    Saviola J
    J Neural Eng; 2005 Mar; 2(1):S1-4. PubMed ID: 15876645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval process for devices and mesh for surgical treatment of pelvic organ prolapse and urinary incontinence.
    Nygaard I
    Clin Obstet Gynecol; 2013 Jun; 56(2):229-31. PubMed ID: 23632639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the 2017 US Food and Drug Administration Circulatory System Devices Panel meeting on the Sentinel Cerebral Protection System.
    Rogers T; Alraies MC; Torguson R; Waksman R
    Am Heart J; 2017 Oct; 192():113-119. PubMed ID: 28938957
    [No Abstract]   [Full Text] [Related]  

  • 12. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A surgeon's perspective of medical device regulation.
    Brantigan JW
    J Spinal Disord; 1995 Oct; 8(5):396-412. PubMed ID: 8563159
    [No Abstract]   [Full Text] [Related]  

  • 14. Europe's plan to tighten regulation of devices will not reach US standards.
    Coombes R
    BMJ; 2012 Sep; 345():e6303. PubMed ID: 22993399
    [No Abstract]   [Full Text] [Related]  

  • 15. Strategic planning for U.S. premarket approval submissions.
    Donawa M
    Med Device Technol; 2006 Sep; 17(7):21-3. PubMed ID: 17039953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming clinical trials in cardiovascular disease: mission critical for health and economic well-being.
    Antman EM; Harrington RA
    JAMA; 2012 Nov; 308(17):1743-4. PubMed ID: 23117771
    [No Abstract]   [Full Text] [Related]  

  • 17. Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies.
    Chen CE; Dhruva SS; Bero LA; Redberg RF
    Arch Intern Med; 2011 Mar; 171(6):534-9. PubMed ID: 21098342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological considerations in observational comparative effectiveness research for implantable medical devices: an epidemiologic perspective.
    Jalbert JJ; Ritchey ME; Mi X; Chen CY; Hammill BG; Curtis LH; Setoguchi S
    Am J Epidemiol; 2014 Nov; 180(9):949-58. PubMed ID: 25255810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices.
    Dhruva SS; Bero LA; Redberg RF
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):165-71. PubMed ID: 21364127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA Netw Open; 2020 Aug; 3(8):e2014496. PubMed ID: 32857145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.